Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LDHA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Target Enzyme / Antigen | LDHA Recombinant Protein (Wild-Type & Hotspot Mutants). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. | View LDHA Products |
| Isoform Counter-Screen | LDHB Recombinant Protein. Critical selectivity counter-screening. Human/Mouse orthologs available. | View LDHB Products |
| Gene Delivery | LDHA Promise-ORF / Lentivirus. Full-length ORF for stable cell lines and Warburg effect modeling. | View LDHA Products |
| Research Antibody | Anti-LDHA Antibody. Recombinant positive control for Western blot, IHC, and target validation. | View LDHA Products |
| Validator | LDHA siRNA Set. For knockdown verification, metabolic flux validation, and specificity controls. | View LDHA Products |
| Glycolysis Partner | PKM (Pyruvate Kinase). Upstream metabolic node for combination therapy studies. | View PKM Products |
| Lactate Export | SLC16A3 (MCT4). Monocarboxylate transporter for pathway biology and resistance bypass analysis. | View SLC16A3 Products |
| Related Target | MCT1. Lactate transporter for combination therapy and metabolic pathway targeting. | View MCT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (LDHA vs LDHB) | Human LDHA and LDHB proteins with >95% purity for side-by-side enzymatic screening; Sequence Verified. |
| Enzymatic Assay Reproducibility | Recombinant enzymes produced with strict QC; Theoretical MW confirmed; High Purity (>95%). |
| Target Engagement Validation | Validated siRNA for genetic knockdown baseline establishment; correlation with pharmacological inhibition. |
| Drug Resistance Screening | Mutant Recombinant Proteins (e.g., active site variants dbSNP rs748436361, rs200093825) available for next-generation inhibitor rational design. |
Live LDHA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LDHA therapeutics is intensifying as researchers focus on the Warburg effect and tumor metabolism. Major players like AstraZeneca, BMS, Novartis, and Roche are shifting from cytotoxic chemotherapy to metabolic checkpoint inhibition. First-generation inhibitors (e.g., FX11 analogs, GNE-140 derivatives) are reaching Phase I trials. The next wave targets isoform-selective allosteric inhibitors and brain-penetrant compounds for glioblastoma. Suppressing LDHA reduces the acidic tumor microenvironment, synergizing with immune checkpoint inhibitors by relieving T-cell suppression. Combination therapies (LDHA inhibitor + PD-1/PD-L1) are expected to enter Phase II by 2025-2027.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | AstraZeneca, BMS, Various Biotechs | Solid Tumors, GBM | Isoform Selectivity Assay (Need high-purity LDHA & LDHB proteins) |
| PROTAC / Degrader | Arvinas, C4 Therapeutics, Academic | Hematologic Malignancies, Resistant Cancers | Cell Permeability & Binding Kinetics (Need native-fold proteins, full-length ORF lentivirus) |
| Combination Therapy | Novartis, Roche | Immunotherapy Refractory | Pathway Analysis (Need PKM & SLC16A3 reagents for combo screening) |
| RNAi / ASO | Alnylam, Ionis, Specialty Pharma | Metabolic Disorders, Autoimmune Diseases | Knockdown Efficiency Validation (Need validated siRNA controls) |
Key Mutations and Resistance Landscape
Important LDHA variants include rs748436361 and rs200093825 (dbSNP), corresponding to active-site mutations. These mutations can drive acquired resistance to first-generation inhibitors. TarMart offers mutant recombinant proteins (e.g., active-site variants) to support rational design of next-generation inhibitors. Resistance mechanisms also include isoform switching (LDHB/LDHC upregulation) and metabolic bypass via oxidative phosphorylation.